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Abstract. We report a study on the importance of factor IX activation in thromboplastin-
dependent coagulation in plasma. Diluted, CaCl2-containing thromboplastin solutions at
constant phospholipid concentration were used to trigger the coagulation in plasma from
patients with congenital factor IX and factor VIII deficiency in the presence and absence of
added factors IX and VIII, and the generation of thrombin activity was monitored. When
coagulation is triggered with the high thromboplastin concentrations normally used in clin-
ical routine tests, the generation of thrombin activity in plasma of patients with congenital
factor IX deficiency before and after reconstitution with purified factor IX appears identical.
When, however, coagulation is triggered with low thromboplastin concentrations, a clear
dependency of the generation of thrombin activity on the concentration of factor IX becomes
evident at factor IX concentrations lower than 30 nM (about 400/o clotting factor activity).
Factor VIII is a compulsory cofactor for this factor IX activity because the prothrombinase
activity at optimal factor IX concentration is still critically dependent upon the amount of
factor VIII present. The lower the amount of thromboplastin, the higher the importance of
factor IX and factor VIII activation in thromboplastin-dependent coagulation. This suggests
a role of this pathway in pathophysiological thrombin formation.
Introduction
In the classical view, factor X can be acti-
vated via two distinct pathways: the intrinsic
pathway and the extrinsic pathway [1, 2]. The
intrinsic pathway is initiated by the so-called
contact activation, which is triggered when
blood comes in contact with foreign surfaces
such as glass [3, 4]. The initial steps of this
pathway involve the four contact factors (fac-
tor XII, prekallikrein, high-molecular-weight
kininogen, factor XI), and the two antihemo-
philic factors (factors IX and VIII).
The extrinsic pathway is initiated when
blood is exposed to tissue thromboplastin.
The reaction sequence involves interaction
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of factor VII and tissue thromboplastin and
subsequent activation of factor X [5]. Thus
both classical pathways converge in the acti-
vation of factor X. The conyersion of pro-
thrombin to thrombin and that of fibrinogen
to fibrin, are common to both pathways.
Evidence for a close interrelationship of
the classical coagulation pathways has accu-
mulated, however. Biggs and Nossel [6]
found that hemophilic plasma did not gener-
ate normal amounts of thrombin activity
when plasma coagulation was triggered with
a diluted thromboplastin solution. Josso and
Prou-Wartelle [7] stated that factor VII was
essential for the procoagulant activity of di-
luted thromboplastin and postulated the im-
portance of antihemophilic factors in the
thromboplastin-dependent pathway [7]. Di-
rect evidence for a possible linkage between
both classical pathways was obtainedby bs-
terud and Rapaport [8]. They clearly showed
that a mixture of factor VII and thrombo-
plastin could activate factor IX in a partially
purified system. This activation step was
studied further by several groups, and it was
clearly shown that factor VIIa in the pres-
ence of thromboplastin can activate both
factor IX and factor X [9-14].
Although numerous studies have postu-
lated that the factor IX activation in throm-
boplastin-dependent coagulation is impor-
tant, attention has mostly focussed on factor
X activation in purifred systems. Clear evi-
dence as to what extent the generation of
thrombin in plasma is mediated via throm-
boplastin-induced factor IX activation is
lacking. In fact, the importance of the factor-
IX-dependent reinforcement loop in the ex-
trinsic pathway has been questioned [15]. In
order to obtain a better impression of the rel-
ative importance of the thromboplastin-in-
duced factor IX activation during the clot-
ting of normal plasma we studied the effect
of thromboplastin concentration on the gen-
eration of thrombin activity in factor-IX-
and factor-Vlll-deficient plasma spiked with
different concentrations of purified factor
IX and factor VIII. Due to a recently devel-
oped technique, we could quantitate their
effects on thrombin generation in terms of
prothrombinase activity tl6l. With this
method, the prothrombin conversion veloc-
ity (i.e. the prothrombinase activity) as a
function of time is calculated from the
thrombin generation curve. The basis of the
method is that at any mdment the observed
thrombin generation velocity (g) is the sum
of the prothrombin conversion velocity (p)
and the negative thrombin breakdown veloc-
ity (b). The breakdown velocity can be calcu-
lated from the amount of thrombin present
and the breakdown constants of thrombin in
plasma. Once this velocity is known, the pro-
thrombin conversion can be calculated as
the sum of g and b (p: g + b).
Materials and Methods
Hemophiliacs
Diagnosis of both hemophilia A and B was based
on a positive family history with a recessive sex-
linked inheritance, joint and deep muscle bleeding
and a prolonged partial thromboplastin time. The
activity of the clotting factors VIII and IX was quan-
titatively determined by a one-stage method accord-
ing to Josso and Prou-Wartelle [17]. The factor VIII
activity in hemophilia A plasma and the factor IX
activity in hemophilia B plasma were (0.8 and
l.5ol0, respectively.
Hemophilic Plasma
Blood from hemophiliacs (A and B) was collected
intrisodium citrate(9 volofbloodto l vol of 0.13M
trisodium citrate) and centrifuged twice for 1 5 min at
3,000 g at I 5 'C, and then for 60 min at 23,000 g at
4 ' C. Plasma was stored in I -ml aliquots at - 80 ' C.
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Thromboplastin
Human brain thromboplastin was prepared by a
modification of the method of Owren and Aas [8].
The crude preparation obtained was homogenized in
a Potter-Elvehjem homogenizer for 3 min and centri-
fuged for l5 min at 2,000 g at room temperature. The
preparation was stored in 0.l-ml aliquots at -20" C.
Prior to use, it was thawed, diluted with 0.05 MTris-
HCI (pH7.35) containing 0.1 M CaClz and pre-
warmed for I h at 37'C. The 1/40 diluted thrombo-
plastin gave a clotting time of 80 s with normal non-
defrbrinated plasma under the same conditions as
used for the thrombin generation experiments.
Phospholipid
Phospholipid vesicles containing 200/o phosphati-
dylserine (PS) and 800/o phosphatidylcholine (PC)
were prepared as described by Rosing et al. [19].
Proteins
Bovine factor IX was prepared as described by
Fujikawa et al. [20]. Bovine factor VIII was prepared
according to Vehar and Davie [21] with the modifica-
tions by van Dieijen et al. 1221.
Chromogenic Substrate
Chromogenic substrate S 2238 (HD-phe-pip-arg-
pnitrophenyl acetate, 2HCl) was obtained from Kabi
Yitrum (Stockholm, Sweden).
Measurement of Thrombin Generation in Plasma
For the measurement of thrombin generation the
procedure described by Hemker et al. [16] was used.
Briefly, 240 pl of defrbrinated plasma and 60 pl of
buffer (Tris-HCl, pH 7.35) were incubated for 4 min
at 37 " C. Thrombin generation was triggered by the
addition of 60 pl of thromboplastin solution contain-
ing 0.1 M CaClz. At frxed time intervals, 10-pl ali-
quots of the incubation mixture were subsampled
into tubes containing 465 pl of buffer (0.05 M Tris-
HCl, 0. 1 M NaC1, 0.50/o albumin and 0.02 M EDTA,
pH 7.9) and 25 pI of 52238 (4mM) at 37'C. The
subsampling tubes were incubated for 2 min at 37 " C,
and then the reaction was stopped by the addition of
300 pl of concentrated acetic acid. The pipettes for
sampling and stopping the reaction were connected to
an Apple IIe computer, programmed to record the
moment of sampling and the moment of stopping the
reaction. The optical density was read at 405 nm ln a
spectrophotometer (LKB-LJltrospec). From the
change in optical density and the time interval be-
tween subsampling and stopping the AOD/min was
automatically calculated.
Measurement of the Decay Constant of
Endogenow Thrombin and Estimation of the
Prothrombin Conversion Velocity
In order to calculate the course ofprothrombinase
activity from the thrombin generation curves, we
determined the decay constant ofendogenous throm-
bin in the plasma used; it was 1 . 1 9 min- r. This decay
constant is the sum ofthe decay constant ofthrombin
by non-o2-macroglobulin (ozM) antiproteases essen-
tially antithrombin III (kr) and the decay constant of
thrombin by o2M (k2). Because the hemophilia B
plasma contained a normal concentration of o2M, we
adopted as k2 the decay constant determined in nor-
mal plasma (k2:0.232 + 0.004min-r '  n :  25)
t l 6 l .
According to Hemker et al. [16], the prothrombin
conversion velocity (prothrombinase activity, ex-
pressed in nanomoles thrombin formed per minute)
was calculated from the thrombin generation data
and the experimentally determined decay constants
of endogenous thrombin. The calculation is based on
the fact that at any moment the experimentally ob-
served rate ofchange ofthe thrombin concentration is
the sum ofthe prothrombin conversion velocity and
the thrombin decay velocity. The latter can be calcu-
lated from the thrombin concentration and the
pseudo first-order decay constants. The fact that part
of the thrombin converts to an amidolytically active
o2M thrombin complex is accounted for.
Results
Generation of Thrombin Activity and
Prothrombinase Activity in
Factor-DeJicient Plasma after Triggering
Coagulation with Dffirent
Concentrations of Tissue Factor
The thrombin formation was studied
either in factor-IX-defrcient plasma (hemo-
philia B plasma) or deficient plasma recon-
stituted with purified factor IX as control.
The coagulation was initiated with different
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Fig. 1. Generation of thrombin
activity in factor-IX-deficient plas-
ma before and after reconstitution
with factor lX (90nM). Coagula-
tion was triggered with a series of
dilutions of thromboplastin in cal-
cium chloride, and phospholipid
was added to a fixed final concen-
tration of I pM. Final thromboplas-
tin dilution in the reaction roix-
tures: l/240 (o); 1 1360 (o); 1/480 (r);
1/600 (n); CaCl2 solution without
thromboplastin (r,). The contin-
uous lines represent the results ob-
tained with hemophilic plasma to
which 90 nM factor IX was added.
The dashed line directly under the
continuous line represents the data
obtained with hemophilic plasma
without addition. The experimental
points are omitted in order not to
overload the hgure.
Contact activation is negligible in our system
due to consistent use of plastic material
throughout the experiment.
Figure I shows that under these condi-
tions the maximal amount of thrombin
formed is greater in the reconstituted plasma
than in plasma of patients with congenital
factor IX deficiency and that the influence of
factor IX on thrombin generation is more
important at low thromboplastin concentra-
tions.
When we calculated prothrombinase ac-
tivities as a function of time and then plotted
the peak prothrombinase activity as a func-
tion of the thromboplastin dilution we ob-
tained the graph shown in figure 2.
It can be seen from figure 2 thatat throm-
boplastin dilutions greater than l:480, the
dilutions of tissue thromboplastin in 0.1 M
CaCl2. At these dilutions, the addition of fac-
tor IX did not influence the generation of
thrombin (results not shown).
In order for the phospholipid concentra-
tion not to be rate limiting, we then added a
final concentration of I p.M PS/PC (20l
80 mole0/o) to all the experiments. The high-
est concentration of tissue thromboplastin
added contributed 0.0221tM of phospholip-
ids, so that the change in phospholipid con-
centration brought about by dilution of tis-
sue tromboplastin could be neglected. When
the phospholipid was added without tissue
thromboplastin, no thrombin generation was
observed (frg.1). From this observation, we
conclude that the phospholipid mixture per
se does not initiate thrombin formation.
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prothrombinase plasma actiyity in plasma of
patients with congenital factor IX deficiency
is lower than that in reconstituted plasma.
Factor IX and Factor VIII Dependency of
Prothrombinase Activity after Triggering
Coagulation with Thromboplastin
In order to investigate the factor IX de-
pendency of thrombin generation after trig-
gering coagulation with thromboplastin, var-
ious quantities of factor IX (15-90 nM) were
added to plasma of patients with congenital
factor IX deficiency. After addition of phos-
pholipid vesicles (l pM) coagulation was
triggered with thromboplastin (final dilution
l:600). The peaks of prothrombinase activ-
ity were calculated from the thrombin gener-
ation curves (Iig. 3).
It is clearly seen in this figure that in the
concentration range tested, factor IX stimu-
lates prothrombinase activity. The curve
suggests a saturation type relationship be-
tween the factor IX concentration and pro-
thrombinase activity. [f normal prothrom-
binase activity is defined as to the activity at
1 00 0/o (90 nM) of factor IX, half normal ac-
tivity was observed at around 15 nM factor
IX (2oo/o).
In order to determine the factor VIII de-
pendency of thrombin generation after trig-
gering coagulation with thromboplastin, var-
ious quantities of factor VIII (0.2-l U/ml)
were added to the plasma of patients with
congenital factor VIII deficiency. Additional
phospholipids (l plf) were again added to
the plasma preparation and the coagulation
was triggered with thromboplastin (frnal di-
lution 1:600). The peak activities of pro-
thrombinase thus obtained are shown in frg-
ure 4.
Increase of the factor VIII concentration
stimulates thrombin generation and again
Fig.2. Maximal prothrombinase activity in fac-
tor-IX-defrcient plasma before and after reconstitu-
tion rvith factor IX (90 DM). Coagulation was trig-
gered with a series of dilutions of thromboplastin in
calcium chloride, and phospholipid was added to a
fixed final concentration of I ttM. o - Factor-IX-defi-
cient plasma; o: reconstituted plasma.
Fig.3. Influence of factor IX on prothrombinase
generation. Coagulation was triggered with thrombo-
plastin (frnal dilution l/600) in calcium chloride and
phospholipid was added to a fixed frnal concentration
of I ttM. Factor IX added to the hemophilic plasma is
expressed in nMlml (frnal concentration).
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Fig.4. Influence offactor VIII on prothrombinase
generation. Coagulation was triggered with thrombo-
plastin (frnal dilution 1/600) in calcium chloride and
phospholipid was added to a frxed frnal concentration
of | 1tM. Factor VIII added to the hemophilic plasma
is expressed in U/ml (final concentration).
the dependency appears to show saturation
characteristics. Half normal prothrombinase
activity was obtained at about 20 0/o of factor
VIII.
Discussion
We studied thrombin generation and pro-
thrombinase activity as a function of time in
human plasma under the influence of low
concentrations of thromboplastin.
In preliminary experiments we saw that,
at high thromboplastin dilution (> l/600),
the generation of thrombin activity in factor-
IX-deficient plasma was markedly reduced.
This result is in accordance with the observa-
tion of Biggs and Nossel [6] who reported
abnormal thrombin generation in plasma of
both hemophilia A and hemophilia B pa-
tients after triggering coagulation with low
amounts of thromboplastin. When, however,
I pM of phospholipid vesicles was added to
the factor-IX-deficient plasma so as to make
thrombin generation independent of the
changes in phospholipid concentration
brought about by dilution of thromboplas-
tin, the importance of factor IX in the pro-
cess of thrombin generation after triggering
coagulation with small amounts of thrombo-
plastin became evident. We therefore carried
out all subsequent experiments in the pres-
ence of I pM phospholipid.
Figures I and 2 show clearly that the in-
fluence of factor IX on prothrombinase ac-
tivity and hence on thrombin generation is
more outspoken at higher thromboplastin
dilutions. Evidently, in situations where
lower amounts of thromboplastin are avail-
able, the interaction between intrinsic and
extrinsic pathway becomes increasingly im-
poftant.
The role of factor VIII as a cofactor in the
factor X activation by factor IXa has been
studied well. In the absence of factor VIIIa
the rate of factor X activation by factor IXa
is extremely low, even in the presence of a
sufficient amount of phospholipids. Factor
VIII brings about a 2. 105-fold increase in the
rate of factor X activation by factor lXal22-
2sl.
The stimulating effects of factor VIII and
factor IX on prothrombinase activity after
triggering coagulation with small amounts of
thromboplastin are comparable; the phe-
nomenon showing saturation characteristics
is represented in frgures 3 and 4.
At the high thromboplastin concentra-
tions used in routine prothrombin tests, the
influence of factors VIII and IX is not seen.
These tests bypass the factor Vll/thrombo-
plastin-factor IX pathway, because the direct
activation of factor X by factor VIIa tissue
thromboplastin is fast. Therefore plasma
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from hemophiliacs will show a nonnal pro-
thrombin time.
The interaction between the intrinsic and
the extrinsic pathways of coagulation might
explain several clinical observations. Some
patients with a deficiency of factor VII have
a serious hemorrhagic diathesis, whereas pa-
tients with deficiencies in the contact activa-
tion system have no signifrcant bleeding ten-
dency, but on the contrary may suffer throm-
boembolic episodes. The frrst patient with
Hageman trait described in the literature
died of pulmonary embolism [26]. The clini-
cal behavior of factor-Xl-deficient individu-
als, some of whom are asymptomatic,
whereas others have a serious bleeding ten-
dency, remains enigmatic.
The results presented here show the im-
portance of factors IX and VIII in the throm-
boplastin-dependent coagulation process in
those situations in which trace amounts of
thromboplastin are present. If we admit that
in vivo triggering of thrombin formation by
low amounts of thromboplastin is the rule
rather than the exception, this might explain
why in hemophiliacs the defrciencies of the
intrinsic pathway are not compensated by
the intact extrinsic pathway.
Circumstantial evidence for this view
may be obtained by the clinical observation
that hemophiliacs tend to bleed in thrombo-
plastin-poor organs like muscles and joints
rather than in thromboplastin-rich organs
like the lungs and brain [27].
As Josso and Prou-Wartelle [7] were the
first to unequivocally demonstrate the role
of the antihemophilic factors in the extrinsic
pathway, we propose to call the factor-Vlll-
and IX-dependent prothrombinase forma-
tion induced by tissue thromboplastin the
'Josso pathway' in honor of the late Frangois
Josso, professor of haematology in Paris.
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